CD Protein Inhibitors 

  Products    Products    Diseases    News 


«12...5758596061626364656667...39323933»
  • ||||||||||  Orencia (abatacept) / BMS
    Preclinical, Journal:  Abatacept inhibits Th17 differentiation and mitigates ?-synuclein-induced dopaminergic dysfunction in mice. (Pubmed Central) -  Aug 17, 2024   
    We found that abatacept treatment decreased Th1 (IFN?+ CD4+) and Th17 (IL17+ CD4+) cells in the brain, rescued motor function and prevented dopaminergic neuronal loss in ?SYN-infused mice. These results highlight the significance of effector CD4+ T cells, especially Th17, in the progression of PD and introduce novel possibilities for repurposing immunomodulatory drugs used for arthritis as PD-modifying therapies.
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group
    Retrospective data, Journal, Metastases:  Toxicity profile of camrelizumab-based immunotherapy in older adults with advanced cancer. (Pubmed Central) -  Aug 17, 2024   
    These results highlight the significance of effector CD4+ T cells, especially Th17, in the progression of PD and introduce novel possibilities for repurposing immunomodulatory drugs used for arthritis as PD-modifying therapies. In this study, older (??70
  • ||||||||||  enoblituzumab (MGA271) / MacroGenics
    Journal, PD(L)-1 Biomarker, IO biomarker:  ITGB6 modulates resistance to anti-CD276 therapy in head and neck cancer by promoting PF4+ macrophage infiltration. (Pubmed Central) -  Aug 17, 2024   
    Enoblituzumab, an immunotherapeutic agent targeting CD276, shows both safety and efficacy in activating T cells and oligodendrocyte-like cells against various cancers...Further investigations demonstrate that inhibiting ITGB6 restores sensitivity to PD1 antibodies in mice resistant to anti-PD1 treatment. In summary, our research reveals a resistance mechanism associated with immune checkpoint inhibitor therapy and identifies potential targets to overcome resistance in cancer treatment.
  • ||||||||||  Kimmtrak (tebentafusp-tebn) / Immunocore
    Journal, Metastases:  Tailoring surveillance imaging in uveal melanoma based on individual metastatic risk. (Pubmed Central) -  Aug 17, 2024   
    In summary, our research reveals a resistance mechanism associated with immune checkpoint inhibitor therapy and identifies potential targets to overcome resistance in cancer treatment. Customizing uveal melanoma surveillance to match metastatic risks could transform current practices, ensuring more precise protocols, reducing unnecessary examinations, and directing health care resources to those in greatest need.
  • ||||||||||  Folotyn (pralatrexate) / Aurobindo, Beleodaq (belinostat) / Aurobindo, Assertio, Adcetris (brentuximab vedotin) / Takeda, Pfizer
    Review, Journal:  Peripheral T-cell lymphoma: From biology to practice to the future. (Pubmed Central) -  Aug 17, 2024   
    Edits of the front-line regimens, often called CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)-plus approaches, look more like CHOP-minus strategies, as the toxicity of five-drug regimens often reduces the dose intensity of the added 'novel' drug, nullifying any hope of an advance...Herein, we analyze PTCL through a 2025 lens, highlighting and underscoring walls that have impeded progress. We will critically explore all the clues and the panoramic view of PTCL research.
  • ||||||||||  Imfinzi (durvalumab) / AstraZeneca
    Review, Journal:  Treatment of unresectable stage III non-small cell lung cancer for patients who are under-represented in clinical trials. (Pubmed Central) -  Aug 17, 2024   
    However, cCRT and consolidation durvalumab may be challenging to administer for selected patient populations underrepresented or even excluded in clinical trials: older and/or frail patients; those with cardiovascular or respiratory comorbidities in which treatment-related adverse events may be higher, and patients with pre-existing autoimmune disorders for whom immunotherapy use is controversial. In this narrative review, we discuss the current evidence, challenges, ongoing clinical trials and potential future treatment scenarios in relevant subgroups of patients with locally advanced NSCLC, who are underrepresented in clinical trials.
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Votrient (pazopanib) / Novartis
    Review, Journal:  Proton pump inhibitors and cancer treatments: Emerging evidence against coadministration. (Pubmed Central) -  Aug 17, 2024   
    For these interactions, it is very important to use the precautionary principle and warn patients and physicians about this. In patients who require acid suppression because of severe symptoms, using antacids or H2 blockers could be recommended.
  • ||||||||||  Tzield (teplizumab-mzwv) / Sanofi
    Journal:  Type 1 diabetes prevention clinical trial simulator: Case reports of model-informed drug development tool. (Pubmed Central) -  Aug 17, 2024   
    Despite more than 100?years since the discovery of insulin, teplizumab remains the only FDA-approved therapy to delay progression from Stage 2 to Stage 3 T1D...Herein, we briefly describe the tool and provide instructions for simulating a planned clinical trial with two case studies. This tool will allow for improved clinical trial designs and accelerate efforts seeking to prevent or delay the onset of T1D.
  • ||||||||||  Journal:  Update on the Use of Thrombopoietin-Receptor Agonists in Pediatrics. (Pubmed Central) -  Aug 17, 2024   
    Current developments include testing of avatrombopag and lusutrombopag that are approved for the treatment of thrombocytopenia associated with chronic liver disease (CLD) in adult patients. In pediatric and adolescent medicine, we expect in the near future a broader use of TPO-RAs as first-line treatment in primary ITP, thereby considering immunomodulatory effects that increase the rate of sustained remission off-treatment, and a selective use in rare inherited thrombocytopenias based on current clinical trials.
  • ||||||||||  Adcetris (brentuximab vedotin) / Takeda, Pfizer
    Journal:  Mycosis fungoides refractory to treatment - importance of a multidisciplinary approach. (Pubmed Central) -  Aug 17, 2024   
    This protocol effectively controlled MF, which previous protocols had failed to do. The diagnosis by the dental team was essential for therapeutic change and improvement of the patient's clinical condition without the need for invasive medical procedures.
  • ||||||||||  Benlysta (belimumab) / GSK, Gazyva (obinutuzumab) / Roche, Biogen, Rituxan (rituximab) / Roche
    Expanding Therapeutic Landscape in Lupus Nephritis: Utilization of B Cell Targeted Therapy (Marriott Grand Ballroom 13, Marriott Marquis |) -  Aug 16, 2024 - Abstract #KIDNEYWEEK2024KIDNEY_WEEK_745;    
    With so many options, the practicing nephrologist needs a firm understanding of how and when to use these drugs to optimize outcomes. Learning Objective(s) Describe the pathogenesis of lupus nephritis, with an emphasis on B cells and loss of tolerance Discuss the mechanisms of action and clinical utility of emerging B cell targeting therapies for lupus nephritis Learning Pathway(s) Glomerular Diseases
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
    Review, Journal:  Treatment of Relapsed Acute Lymphocytic Leukemia in Adult Patients. (Pubmed Central) -  Aug 16, 2024   
    Like B-ALL, the only existing approved therapy for relapsed T-ALL, nelarabine, is now used in the upfront treatment setting potentially limiting its utility in relapsed disease. Over the next several years, the hope is for patients diagnosed with T-ALL to experience the drastic improvement in outcomes as has been seen for patients diagnosed with B-ALL over the last decade.
  • ||||||||||  Benlysta (belimumab) / GSK, Actemra IV (tocilizumab) / Roche, JW Pharma, Rituxan (rituximab) / Roche
    Review, Journal:  Systemic-Sclerosis-Related Interstitial Lung Disease: A Review of the Literature and Recommended Approach for Clinical Pharmacists. (Pubmed Central) -  Aug 16, 2024   
    Numerous pharmacologic agents have been studied and repurposed in the treatment of SSc-ILD, with nintedanib and TCZ gaining approval to slow the rate of decline in pulmonary function in SSc-ILD. Other agents, including belimumab and pirfenidone, are on the horizon as potential treatment options; but further studies are needed to compare their efficacy and safety with the current standard of care.
  • ||||||||||  Darzalex (daratumumab) / J&J
    Biomarker, Journal, IO biomarker:  Donor-Derived Cell-Free DNA as a Companion Biomarker for AMR Treatment With Daratumumab: Case Series. (Pubmed Central) -  Aug 16, 2024   
    In both patients, daratumumab treatment led to stabilization of kidney function parameters, a strong decline of dd-cfDNA below the previously established threshold for rejection, and partial or complete histologic resolution of AMR activity. Our case series suggests that dd-cfDNA may be a useful companion biomarker for longitudinal monitoring of anti-CD38 treatment in patients with AMR.
  • ||||||||||  Rituxan (rituximab) / Roche
    Retrospective data, Review, Journal:  B cell depletion for autoimmune liver diseases: A retrospective review of indications and outcomes. (Pubmed Central) -  Aug 16, 2024   
    We retrospectively reviewed rituximab-treated patients between 2017 and 2022...One patient had persistent hypogammaglobulinemia, and another had lymphopenia. B-cell depletion is an effective and safe treatment for autoimmune liver diseases and should be included as an option, particularly for relapsing patients in whom steroids are undesirable or have shown nonadherence.
  • ||||||||||  Ibrance (palbociclib) / Pfizer, Mekinist (trametinib) / Novartis, BeiGene
    Journal:  Separable cell cycle arrest and immune response elicited through pharmacological CDK4/6 and MEK inhibition in RASmut disease models. (Pubmed Central) -  Aug 16, 2024   
    The TBK1(TANK-binding kinase 1) inhibitor GSK8612 selectively blocked the induction of interferon-related genes induced by palbociclib and trametinib treatment, and highlighted the separable epigenetic responses elicited by combined CDK4/6 and MEK inhibition. Together, these findings provide key mechanistic insights into the therapeutic potential of CDK4/6 and MEK inhibition in soft tissue sarcoma.
  • ||||||||||  Mulpleta (lusutrombopag) / Shionogi
    Journal:  Asymmetric Transfer Hydrogenation of Ketones Improved by PNN-Manganese Complexes. (Pubmed Central) -  Aug 15, 2024   
    Notably, Mn2 proved to be the most productive catalyst, allowing an outstanding turnover number of 8300 with catalyst loadings as low as 0.01 mol %. Furthermore, this catalytic protocol shows considerable promise for applications in the synthesis of chiral drugs such as Lusutrombopag.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal, Real-world evidence, Real-world:  A real-world drug safety surveillance study of lenvatinib from the FAERS database. (Pubmed Central) -  Aug 15, 2024   
    FGFR4, PDGFRA, and KIT (Lenvatinib targets) are potentially linked to cholecystitis, cholangitis, and hepatic encephalopathy. We identified Lenvatinib-associated AEs and discovered new AEs that will be useful for clinical monitoring and risk assessment.